nach oben

Der Nervenarzt

Erschienen in:

01.10.2003 | Aktuelles

Mitoxantron zur Therapie der Multiplen Sklerose

verfasst von: B. C. Kieseier, R. Gold, Prof. Dr. H.-P. Hartung

Erschienen in: Der Nervenarzt | Ausgabe 10/2003

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Veröffentlichung der MIMS-Studie (Mitoxantrone in Multiple Sclerosis), die Zulassung durch die deutschen Gesundheitsbehörden sowie die Empfehlungen der MS-Therapie-Konsenus-Gruppe (MSTKG) stützen den therapeutischen Einsatz von Mitoxantron bei Patienten mit aktiver Multipler Sklerose. Der vorliegende Artikel gibt eine Übersicht über relevante vorklinische und klinische Studien, diskutiert relevante unerwünschte Wirkungen der Substanz und definiert den Stellenwert von Mitoxantron im Arsenal der therapeutischen Möglichkeiten im Kampf gegen diese behindernde Erkrankung.

Bellosillo B, Colomer D, Pons G, Gil J (1998) Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol 100:142–6CrossRefPubMed

Boland MP, Fitzgerald KA, O'Neill LA (2000) Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells. J Biol Chem 275:25231–8CrossRefPubMed

Cattaneo C, Almici C, Borlenghi E, Motta M, Rossi G (2003) A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis. Leukemia 17:985–986CrossRefPubMed

Chan A, Weilbach FX, Toyka KV, Gold R (2002) Mitoxantrone-induced immunological changes in mitoxantrone-induced immunological changes in peripheral blood leukocytes of MS-patients. Mult Scler 8:S69

Doroshow JH (1983) Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase. Cancer Res 43:4543–5451

Edan G, Miller D, Clanet M et al. (1997) Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62:112–118PubMed

Edan G, Morrissey SP, Hartung HP (2002) Use of mitoxantrone to treat multiple sclerosis. In: Cohen JA, Rudick RA (eds) Multiple Sclerosis Therapeutics. Martin Dunitz, London, pp 403–426

Ehrke MJ, Maccubbin D, Ryoyama K, Cohen SA, Mihich E (1986) Correlation between adriamycin-induced augmentation of interleukin 2 production and of cell-mediated cytotoxicity in mice. Cancer Res 46:54–60PubMed

Faulds D, Balfour JA, Chrisp P, Langtry HD (1991) Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 41:400–449PubMed

10.

Fidler JM, DeJoy SQ, Gibbons JJ Jr (1986) Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J Immunol 137:727–732PubMed

11.

Fidler JM, DeJoy SQ, Smith FR, 3rd, Gibbons JJ Jr (1986) Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice. J Immunol 136:2747–2754PubMed

12.

Gbadamosi J, Buhmann C, Tessmer W, Moench A, Haag F, Heesen C (2003) Effects of Mitoxantrone on Multiple Sclerosis Patients' Lymphocyte Subpopulations and Production of Immunoglobulin, TNF-alpha and IL-10. Eur Neurol 49:137–141CrossRefPubMed

13.

Ghalie RG, Edan G, Laurent M et al. (2002) Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 59:909–913PubMed

14.

Ghalie RG, Mauch E, Edan G et al. (2002) A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 8:441–445CrossRefPubMed

15.

Gonsette RE, Demonty L (1990) Immunosuppression with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients. Neurology 40:S261

16.

Hartung HP, Gonsette R, Konig N et al. (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360:2018–2025CrossRefPubMed

17.

Heesen C, Bruegmann M, Gbdamosi J, Koch E, Monch A, Buhmann C (2003) Therapy-related acute myelogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with mitoxantrone. Mult Scler 9:213–214CrossRefPubMed

18.

Herman EH, Zhang J, Rifai N et al. (2001) The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. Cancer Chemother Pharmacol 48:297–304CrossRefPubMed

19.

Kappos L, Gold R, Hofmann E, Keil W, Clauß R (1992) Multiple sclerosis: diagnostic criteria and the role of contrast-enhanced MRI. Medicom 127–135

20.

Lenk H, Müller U, Tanneberger S (1987) Mitoxantrone: mechanism of action, antitumor activity, pharmacokinetics, efficacy in the treatment of solid tumors and lymphomas, and toxicity. Anticancer Res 7:1257–1264PubMed

21.

Levine S, Saltzman A (1986) Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone. J Neuroimmunol 13:175–181CrossRefPubMed

22.

Lublin FD, Lavasa M, Viti C, Knobler RL (1987) Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin Immunol Immunopathol 45:122–128PubMed

23.

Mauch E, Kornhuber HH, Krapf H, Fetzer U, Laufen H (1992) Treatment of multiple sclerosis with mitoxantrone. Eur Arch Psychiatry Clin Neurosci 242:96–102PubMed

24.

Millefiorini E, Gasperini C, Pozzilli C et al. (1997) Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 244:153–159CrossRefPubMed

25.

Mogenet I, Simiand-Erdociain E, Canonge JM, Pris J (2003) Acute myelogenous leukemia following mitoxantrone treatment for multiple sclerosis. Ann Pharmacother 37:747–748CrossRef

26.

Noseworthy JH, Hopkins MB, Vandervoort MK et al. (1993) An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 43:1401–1406PubMed

27.

Pette M, Gold R, Pette DF, Hartung HP, Toyka KV (1995) Mafosfamide induces DNA fragmentation and apoptosis in human T-lymphocytes. A possible mechanism of its immunosuppressive action. Immunopharmacology 30:59–69CrossRefPubMed

28.

Pette M, Hartung HP (2003) Mitoxantrontherapie bei multipler Sklerose—Stand 2002. Akt Neurol 30:71–75CrossRef

29.

Ridge SC, Sloboda AE, McReynolds RA, Levine S, Oronsky AL, Kerwar SS (1985) Suppression of experimental allergic encephalomyelitis by mitoxantrone. Clin Immunol Immunopathol 35:35–42PubMed

30.

Rieckmann P, Toyka KV (2002) Immunmodulatorische Stufentherapie der Multiplen Sklerose. Nervenarzt 73:556–563CrossRefPubMed

31.

Robison TW, Giri SN (1986) Effects of chronic administration of doxorubicin on myocardial beta-adrenergic receptors. Life Sci 39:731–736CrossRefPubMed

32.

Seymour L, Bramwell V, Moran LA (1999) Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Cancer Prev Control 3:145–159PubMed

33.

Singal PK, Deally CM, Weinberg LE (1987) Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol 19:817–828PubMed

34.

Singal PK, Pierce GN (1986) Adriamycin stimulates low-affinity Ca2+ binding and lipid peroxidation but depresses myocardial function. Am J Physiol 250:H419–425PubMed

35.

Spindler M, Weilbach FX, Beer M et al. (2003) Non-invasive functional and biochemical assessment of mitroxantrone cardiotoxicity in patients with multiple sclerosis. J Cardiovasc Pharmacol. In press

36.

Vicari AM, Ciceri F, Folli F, Lanzi R, Colombo B, Comi G, Camba L (1998) Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis. Leukemia 12:441–442CrossRefPubMed

37.

Weilbach FX, Toyka KV, Gold R (2000) Combination therapy with the iron chelator dexrazoxane augments therapeutic efficacy of mitoxantone in experimental autoimmune encephalomyelitis in Lewis rats. Rev Neurol 156:127PubMed

38.

Wiendl H, Kieseier BC (2003) Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies. Expert Opin Investig Drugs 12:689–712PubMed

Titel: Mitoxantron zur Therapie der Multiplen Sklerose
verfasst von: B. C. Kieseier
R. Gold
Prof. Dr. H.-P. Hartung
Publikationsdatum: 01.10.2003
Verlag: Springer-Verlag
Erschienen in: Der Nervenarzt / Ausgabe 10/2003
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI: https://doi.org/10.1007/s00115-003-1566-6

Neu in den Fachgebieten Neurologie und Psychiatrie

23.04.2024 | Demenz | Nachrichten

Springer Medizin

Mitoxantron zur Therapie der Multiplen Sklerose

Zusammenfassung

Neu in den Fachgebieten Neurologie und Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2003

Lamotrigin bei Frauen mit Epilepsie

Das vomeronasale Organ des Menschen

Evidenzbasierte Armrehabilitation

Spätmanifestation einer Glykogenose Typ II

Erhöhte zerebrale Erregbarkeit und "spreading depression"

Chemokine

Neu in den Fachgebieten Neurologie und Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein